Genetic Causes of Hereditary Myopathies in a Cohort of Male Patients: Molecular Diagnosis in Myopathies
The Journal of Applied Laboratory Medicine · 2026
DOI: 10.1093/jalm/jfaf157 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Paola Ayala-Ramírez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Human Genetics Institute, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Dystrophin, Muscular Diseases, Molecular Diagnostic Techniques. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vitalchem Laboratories of Colombia and PintPharma, Research Vicerrectory of the Pontificia Universidad Javeriana.
Abstract (Originalsprache)
Background
Hereditary myopathies are a heterogeneous group of genetic disorders affecting skeletal muscle. The molecular diagnosis of these conditions has been revolutionized by next-generation sequencing (NGS), significantly improving diagnostic accuracy. This study aimed to characterize the genetic causes of primary myopathies in a cohort of Colombian male patients.
Methods
A total of 175 male individuals with clinical suspicion of hereditary myopathy were evaluated. Multiplex ligation-dependent probe amplification (MLPA) was performed to detect deletions/duplications in the DMD gene, and targeted NGS panel sequencing was applied in MLPA-negative cases and those with single-exon deletions.
Results
MLPA identified DMD deletions or duplications in 44.6% (78/175) of patients, confirming Duchenne/Becker muscular dystrophy (DBMD). NGS was performed in 97 patients, revealing pathogenic or likely pathogenic variants in 30.4% (17/56) of the analyzed genes. The overall diagnostic yield of the combined MLPA and NGS strategy was 85.7% (150/175). DBMD was the most frequent diagnosis (74.3%; 130/175), followed by limb-girdle muscular dystrophies (5.7%; 10/175). NGS also identified 38 variants of uncertain significance (VUS) in 43.3% (42/97) of analyzed samples.
Conclusions
The combined use of MLPA and targeted NGS improves the molecular diagnosis of hereditary myopathies. This approach provides insights into the genetic landscape of neuromuscular disorders, enabling better clinical management, genetic counseling, and potential eligibility for emerging therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Human Genetics Institute, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
- Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
ORCID-Profile: Paola Ayala-Ramírez
Förderung
- Vitalchem Laboratories of Colombia and PintPharma
- Research Vicerrectory of the Pontificia Universidad Javeriana
Zitieren
APA
Ayala-Ramírez, P., García-Acero, M., Guerra-Torres, M., Suárez-Obando, F., Pineda, T., Buitrago, T., & García-Robles, R. (2026). Genetic Causes of Hereditary Myopathies in a Cohort of Male Patients: Molecular Diagnosis in Myopathies. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf157
Vancouver
Ayala-Ramírez P, García-Acero M, Guerra-Torres M, Suárez-Obando F, Pineda T, Buitrago T, et al. Genetic Causes of Hereditary Myopathies in a Cohort of Male Patients: Molecular Diagnosis in Myopathies. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfaf157
BibTeX
@article{AyalaRamrez2026,
author = {Ayala-Ramírez, Paola and García-Acero, Mary and Guerra-Torres, Mariana and Suárez-Obando, Fernando and Pineda, Tatiana and Buitrago, Tatiana and García-Robles, Reggie},
title = {Genetic Causes of Hereditary Myopathies in a Cohort of Male Patients: Molecular Diagnosis in Myopathies},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
doi = {10.1093/jalm/jfaf157}
}
EUVIMED